Worth Venture Partners’s Neurogene NGNE Stock Holding History

Worth Venture Partners’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,475	Closed	-$78K	–	183
2018 Q2	$78K	Buy	+1,475	New	+$384K	0.06%	73

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Worth Venture Partners's NGNE Position: Q3 2018 in Review

Worth Venture Partners sold out of Neurogene (NGNE) in Q3 2018, closing a stake of 1,475 shares — an estimated $78K sold.

Worth Venture Partners first reported a position in NGNE in Q2 2018 and held it in 1 quarter. The position peaked at $78K in Q2 2018. 45 funds tracked by Wall St. Rank hold NGNE as of Q3 2018.

Worth Venture Partners reported no remaining Neurogene position as of Q3 2018 after selling out during the quarter.
Worth Venture Partners sold 1,475 Neurogene shares in Q3 2018, an estimated $78K.
Worth Venture Partners first reported a position in Neurogene in Q2 2018 and held it in 1 quarter.
Worth Venture Partners's Neurogene position peaked at $78K in Q2 2018.
45 funds tracked by Wall St. Rank held Neurogene as of Q3 2018.

Based on Worth Venture Partners's 13F filing for Q3 2018, filed 15 Nov 2018.